Ad-RTVP-1

Ad-RTVP-1 is a replication-deficient adenoviral vector-based gene therapy designed to deliver the human RTVP-1 (Reduced Expression in Transition Vaginal Prostatic-1) gene, also known as GLIPR1 (Glioma Pathogenesis-Related Protein 1). RTVP-1 is a potent pro-apoptotic protein that is frequently downregulated in prostate cancer tissues. Upon intratumoral administration, the vector mediates the overexpression of RTVP-1, which triggers apoptosis in cancer cells through the activation of the c-Jun N-terminal kinase (JNK) pathway and the induction of endoplasmic reticulum stress. Beyond direct cytotoxicity, Ad-RTVP-1 treatment has been observed to promote an immunogenic cell death environment, recruiting and activating dendritic cells and T-cells to generate a systemic anti-tumor immune response. It has been primarily evaluated in clinical trials for the treatment of localized and metastatic prostate cancer.

Other names

Adenoviral RTVP-1Adenovirus-mediated RTVP-1 gene therapy